Skip to main content
. 2020 Jun;59(Suppl 1):73–80. doi: 10.20471/acc.2020.59.s1.09

Figure 1.

Figure 1

(a) Whole-body iodine-131 scan of patient demonstrating no visible uptake at the moment of disease progression with loss of previous well radioiodine accumulation, and (b) Whole-body scan of the same patient six months after vemurafenib therapy demonstrating intensive uptake in lung metastases (leading to redifferentiation of thyroid cancer cells and restoration of radioiodine uptake).